HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human
HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

The purity of HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.

HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
Z06610
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer[Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and IVCPICSQK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&IVCPICSQK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

    The purity of HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human

    HLA-A*11:01&B2M&HPV16 E7 (IVCPICSQK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.


Background
Target Background HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
Synonyms HPV16; E7; MHC

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.